EFFECT OF COMBINATION CHEMOTHERAPY WITH CISPLATIN AND CYCLOPHOSPHAMIDE ON HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SURROGATE MARKERS IN A PATIENT WITH ADVANCED EPITHELIAL OVARIAN-CANCER

This is the first report to evaluate the effects of combination chemot herapy on HIV-1 surrogate markers in an HIV-1-infected patient with an advanced epithelial ovarian cancer. Cisplatin combined with cyclophos phamide was well-tolerated, without significant changes in the HIV-1 p 24 antigen, neopterin, beta(2)-mieroglobulin, and CD4 values. The pati ent demonstrated a chemical and clinical response to therapy, without evidence of opportunistic infection or severe neutropenia. During the 6-month period of observation, treatment with cisplatin and cyclophosp hamide did not significantly increase the risk of HIV-1 disease progre ssion. (C) 1995 Academic Press, Inc.